1
|
Monteiro GN, Monteiro DS, Oliveira RJ, Cunha-Laura AL, Amaral EA, Auharek SA. Testicular toxicity in mice exposed to terephthalic acid in utero and during lactation. Environ Sci Pollut Res Int 2023; 30:66050-66061. [PMID: 37097558 DOI: 10.1007/s11356-023-26849-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/29/2022] [Accepted: 04/03/2023] [Indexed: 05/17/2023]
Abstract
Terephthalic acid (TPA) is a worldwide aromatic compound widely used to manufacture resins and the raw material for the polymerization reaction with ethylene glycol to produce polyethylene terephthalate, known as PET. The use of TPA extends to the synthesis of phthalates, plasticizers used in various industrialized products such as toys and cosmetics. The present study aimed to evaluate the testicular toxicity of terephthalic acid on male mice exposed in utero and during lactation to TPA in different developmental windows. The animals were treated intragastric with TPA at stock dispersal dosages corresponding to 0.0014 g/ml and 0.56 g/ml of TPA in 0.5% v/v carboxymethylcellulose as well as the control dose, composed solely of dispersion of carboxymethylcellulose (0.5% v/v). Four experimental windows were established: group I-treatment in utero, in the fetal period (gestational day-GD 10.5-18.5), with euthanasia at GD 18.5; group II-treatment in utero, in the fetal period (GD 10.5-18.5) and the lactational period (postnatal day (PND-15)), with euthanasia at 15 days; group III-treatment in utero in the fetal period (DG 10.5-18.5) with euthanasia at 70 days (age of sexual maturity, PND 70); group IV-treatment in utero, in the fetal period (GD 10.5-18.5) and the lactational period (PND-15), with euthanasia at 70 days (PND70). The results indicate that TPA changes the reproductive parameters (testicular weight, GI, penis size, and anogenital index) only at the dose of 0.56 g/ml in the fetal period. Data on the volumetric ratio of the testis elements show that the dispersion with the highest concentration of TPA significantly altered the blood vessel/capillary, lymphatic vessel, and connective tissue percentages. Only at the dose of 0.56 g/ml TPA was it effective in decreasing the Leydig and Sertoli cell numbers of the euthanized animals at GD 18.5. In group II, TPA increased the diameter and lumen of seminiferous tubules, which indicates that TPA accelerated the maturation process of Sertoli cells without changing the number and the nuclear volume of these cells. The Sertoli and Leydig cell numbers of the 70-day animals exposed to TPA in the gestational and lactational period were similar to the control. Therefore, the present study is the first in the literature to show that TPA presents a testicular toxicity during fetal (DG18.5) and postnatal life (PND15), without repercussion in adulthood (70 days).
Collapse
Affiliation(s)
- Gustavo Nazareno Monteiro
- Faculdade de Medicina Do Mucuri (FAMMUC), Universidade Federal Dos Vales Do Jequitinhonha E Mucuri (UFVJM), Teófilo Otoni, Minas Gerais, Brazil
- Instituto de Ciência, Engenharia E Tecnologia (ICET), Universidade Federal Dos Vales Do Jequitinhonha E Mucuri (UFVJM), Teófilo Otoni, Minas Gerais, Brazil
| | - Douglas Santos Monteiro
- Instituto de Ciência, Engenharia E Tecnologia (ICET), Universidade Federal Dos Vales Do Jequitinhonha E Mucuri (UFVJM), Teófilo Otoni, Minas Gerais, Brazil
| | - Rodrigo Juliano Oliveira
- Centro de Estudos Em Células Tronco, Terapia Celular E Genética Toxicológica (CeTroGen), Hospital Universitário Maria Aparecida Pedrossian (HUMAP), Universidade Federal de Mato Grosso Do Sul (UFMS), Campo Grande, Mato Grosso Do Sul, Brazil
| | - Andréa Luiza Cunha-Laura
- Instituto de Biologia (INBIO), Universidade Federal de Mato Grosso Do Sul (UFMS), Campo Grande, Mato Grosso Do Sul, Brazil
| | - Ernani Aloysio Amaral
- Faculdade de Medicina Do Mucuri (FAMMUC), Universidade Federal Dos Vales Do Jequitinhonha E Mucuri (UFVJM), Teófilo Otoni, Minas Gerais, Brazil
| | - Sarah Alves Auharek
- Faculdade de Medicina Do Mucuri (FAMMUC), Universidade Federal Dos Vales Do Jequitinhonha E Mucuri (UFVJM), Teófilo Otoni, Minas Gerais, Brazil.
| |
Collapse
|
2
|
Auharek SA, Carollo CA, Oliveira RJ, Cunha-Laura AL, Monreal ACD, Siqueira JM, Costa DS, de Paiva Condé TR, Wollf DIL, Aloysio Amaral E. Evaluation of the testis function of mice exposed in utero and during lactation to Pfaffia glomerata (Brazilian ginseng). Andrologia 2019; 51:e13328. [PMID: 31145510 DOI: 10.1111/and.13328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2019] [Revised: 04/25/2019] [Accepted: 05/05/2019] [Indexed: 11/28/2022] Open
Abstract
Pfaffia glomerata (Spreng.) Pedersen, popularly known as "Brazilian ginseng," is used as medicinal plant in Brazil to treat inflammatory diseases in general. Previous studies showed that its extract increases the nitric oxide (NO) levels. Knowing that NO downregulates steroidogenesis and that alterations in the action/production of androgens during perinatal life could alter testis development, the present studies sought to investigate the reproductive toxicity of Pfaffia glomerata on male mice exposed to hydroalcoholic extract in utero and during lactation. The present study shows that P. glomerata extract does not alter body weight, tubular diameter and testis function in male mice. Although a reduction in the testis weight was observed in the animals that received the highest dose directly in early post-natal life, our findings show clearly that P. glomerata may not act as an endocrine disruptor, and it is not an "antiandrogenic" compound that could lead to testicular dysgenesis syndrome.
Collapse
Affiliation(s)
- Sarah Alves Auharek
- Faculdade de Medicina do Mucuri (FAMMUC), Universidade Federal dos Vales do Jequitinhonha e Mucuri (UFVJM), Teófilo Otoni, Brazil
| | - Carlos Alexandre Carollo
- Programa de pós-graduação em Farmácia, Centro de Ciências Biológicas e da Saúde (CCBS), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Brazil
| | - Rodrigo Juliano Oliveira
- Programa de pós-graduação em Farmácia, Centro de Ciências Biológicas e da Saúde (CCBS), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Brazil.,Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica (CeTroGen), Núcleo de Hospital Universitário (NHU), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Brazil
| | - Andréa Luiza Cunha-Laura
- Programa de pós-graduação em Farmácia, Centro de Ciências Biológicas e da Saúde (CCBS), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Brazil
| | - Antônio Carlos Duenhas Monreal
- Programa de pós-graduação em Farmácia, Centro de Ciências Biológicas e da Saúde (CCBS), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Brazil
| | - João Máximo Siqueira
- Universidade Federal de São João Del-Rei (UFSJ), Divinópolis, Minas Gerais, Brazil
| | - Deiler Sampaio Costa
- Faculdade de Medicina Veterinária e Zootecnia (FAMEZ), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Brazil
| | - Tammy Reis de Paiva Condé
- Faculdade de Medicina do Mucuri (FAMMUC), Universidade Federal dos Vales do Jequitinhonha e Mucuri (UFVJM), Teófilo Otoni, Brazil
| | - Dayhanne Isa Langkammer Wollf
- Faculdade de Medicina do Mucuri (FAMMUC), Universidade Federal dos Vales do Jequitinhonha e Mucuri (UFVJM), Teófilo Otoni, Brazil
| | - Ernani Aloysio Amaral
- Faculdade de Medicina do Mucuri (FAMMUC), Universidade Federal dos Vales do Jequitinhonha e Mucuri (UFVJM), Teófilo Otoni, Brazil
| |
Collapse
|
3
|
Vani JM, de Carvalho Schweich L, de Oliveira KRW, Auharek SA, Cunha-Laura AL, Antoniolli-Silva ACMB, Nazario CED, Oliveira RJ. Evaluation of the effects of the larvicides temephos on reproductive performance, embryofetal development and DNA integrity of Swiss mice. Pestic Biochem Physiol 2018; 148:22-27. [PMID: 29891373 DOI: 10.1016/j.pestbp.2018.03.010] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/10/2017] [Revised: 03/05/2018] [Accepted: 03/23/2018] [Indexed: 06/08/2023]
Abstract
Temephos is considered the gold standard by the Ministry of Health for controlling the larvae of the mosquito Aedes aegypti. The present study evaluated the effects of Temephos larvicide on the reproductive performance, embryo-fetal development and DNA integrity of Swiss mice. This study used 30 pregnant female mice: 10 were controls treated with drinking water at a dosage of 0.1 mL/10 g (body weight - b.w., administered orally - a.o.), and 20 were treated with Temephos at doses of 0.0043 mg/kg and 0.043 mg/kg (b.w., a.o.) during the gestational period. Statistical analysis showed that Temephos did not alter the biometric or reproductive parameters. Comparing the weight of the fetus to the stage of pregnancy demonstrated that the 0.0043 mg/kg dosage increased the size of the fetuses. No external malformations were detected. However, the 0.043 mg/kg dosage induced changes in the sternum, with the main change being the center of the sternum, xiphoid processes and absence of the manubrium. The other skeletal and visceral alterations did not differ from the control group and are considered variants of normality. The analysis of head measurements showed an increase in the anterior/posterior measurements of the glabella, the external occipital protuberance and the biauricular plane. The circumference and area of the head did not present significant differences. The micronucleus test showed only a 0.043 mg/kg increase in 48 h. Thus, it is considered that Temephos has a low teratogenic and genotoxic risk.
Collapse
Affiliation(s)
- Juliana Miron Vani
- Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen, Hospital Universitário Maria Aparecida Pedrossian - HUMAP, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil; Programa de Pós-graduação em Saúde e Desenvolvimento na Região Centro-Oeste, Faculdade de Medicina "Dr. Hélio Mandetta" - FAMED, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil
| | - Laynna de Carvalho Schweich
- Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen, Hospital Universitário Maria Aparecida Pedrossian - HUMAP, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil; Programa de Pós-graduação em Saúde e Desenvolvimento na Região Centro-Oeste, Faculdade de Medicina "Dr. Hélio Mandetta" - FAMED, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil
| | - Karla Regina Warszawski de Oliveira
- Programa de Pós-graduação em Química - INQUI, Universidade Federal de Mato Grosso do Sul- UFMS, Campo Grande, MS, Brazil; Laboratório de Combustiveis - LABCOM, Instituto de Química - INQUI, Universidade Federal de Mato Grosso do Sul- UFMS, Campo Grande, MS, Brazil
| | - Sarah Alves Auharek
- Faculdade de Medicina do Mucuri, Universidade Federal dos Vales do Jequitinhonha e do Mucuri - UFVJM, Teófilo Otoni, MG, Brazil
| | - Andréa Luiza Cunha-Laura
- Programa de Mestrado em Farmácia, Instituto de Biociências - INBIO, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil
| | - Andréia Conceição Millan Brochado Antoniolli-Silva
- Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen, Hospital Universitário Maria Aparecida Pedrossian - HUMAP, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil; Programa de Pós-graduação em Saúde e Desenvolvimento na Região Centro-Oeste, Faculdade de Medicina "Dr. Hélio Mandetta" - FAMED, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil
| | - Carlos Eduardo Domingues Nazario
- Programa de Pós-graduação em Química - INQUI, Universidade Federal de Mato Grosso do Sul- UFMS, Campo Grande, MS, Brazil; Laboratório de Combustiveis - LABCOM, Instituto de Química - INQUI, Universidade Federal de Mato Grosso do Sul- UFMS, Campo Grande, MS, Brazil
| | - Rodrigo Juliano Oliveira
- Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen, Hospital Universitário Maria Aparecida Pedrossian - HUMAP, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil; Programa de Pós-graduação em Saúde e Desenvolvimento na Região Centro-Oeste, Faculdade de Medicina "Dr. Hélio Mandetta" - FAMED, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil; Programa de Pós-graduação em Genética e Biologia Molecular, Centro de Ciências Biológicas - CCB, Universidade Estadual de Londrina, Londrina, PR, Brazil.
| |
Collapse
|
4
|
Ishikawa RB, Vani JM, das Neves SC, Rabacow APM, Kassuya CAL, Croda J, Cardoso CAL, Monreal ACDF, Antoniolli ACMB, Cunha-Laura AL, Oliveira RJ. The safe use of Doliocarpus dentatus in the gestational period: Absence of changes in maternal reproductive performance, embryo-fetal development and DNA integrity. J Ethnopharmacol 2018; 217:1-6. [PMID: 29408581 DOI: 10.1016/j.jep.2018.01.034] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/20/2017] [Revised: 01/26/2018] [Accepted: 01/29/2018] [Indexed: 05/22/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Doliocarpus dentatus (Dilleniaceae) is commonly used in Brazil for the treatment of inflammatory process pain and urinary retention. Previous studies of our group have demonstrated the anti-inflammatory and antimycobacterial action of the ethanolic extract of Doliocarpus dentatus (EEDd) as well as the safety of its use. AIM OF THE STUDY we investigated the effects of EEDd on reproductive performance, fetal development and DNA integrity in pregnant female Swiss mice. MATERIAL AND METHODS thirty female Swiss mice were divided into three experimental groups (n = 10): control group treated with 1% tween-80 and EEDd1 and EEDd2 groups treated with EEDd at doses of 100 and 1000 mg/kg, respectively. The treatment occurred by oral gavage throughout the gestational period. At the end of pregnancy, parameters related to reproductive performance, embryofoetal development and DNA integrity was evaluated. RESULTS both doses of the extract tested did not alter the reproductive parameters, did not present significant differences in the embryofetal development when compared to the control group and also did not induce the formation of micronuclei. CONCLUSION the EEDd do not alter the reproductive parameters, embryofetal development and DNA integrity, ensuring its safe use during pregnancy.
Collapse
Affiliation(s)
- Raissa Borges Ishikawa
- Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica (CeTroGen), Hospital Universitário Maria Aparecida Pedrossian (HUMAP), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil; Programa de Mestrado em Farmácia, Faculdade de Ciências Farmacêuticas, Alimentos e Nutrição (FACFAN), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil.
| | - Juliana Miron Vani
- Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica (CeTroGen), Hospital Universitário Maria Aparecida Pedrossian (HUMAP), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil; Programa de Pós-graduação em Saúde e Desenvolvimento na Região Centro-Oeste, Faculdade de Medicina Dr. Hélio Mandetta (FAMED), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil.
| | - Silvia Cordeiro das Neves
- Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica (CeTroGen), Hospital Universitário Maria Aparecida Pedrossian (HUMAP), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil; Programa de Mestrado em Farmácia, Faculdade de Ciências Farmacêuticas, Alimentos e Nutrição (FACFAN), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil.
| | - Ana Paula Maluf Rabacow
- Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica (CeTroGen), Hospital Universitário Maria Aparecida Pedrossian (HUMAP), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil; Programa de Pós-graduação em Saúde e Desenvolvimento na Região Centro-Oeste, Faculdade de Medicina Dr. Hélio Mandetta (FAMED), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil.
| | | | - Júlio Croda
- Faculdade de Ciências da Saúde, Universidade Federal da Grande Dourados (UFGD), Dourados, Mato Grosso do Sul, Brazil.
| | - Claudia Andrea Lima Cardoso
- Centro de Estudos em Recursos Naturais, Universidade Estadual de Mato Grosso do Sul (UEMS), Dourados, Mato Grosso do Sul, Brazil.
| | - Antônio Carlos Duenhas Ferreira Monreal
- Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica (CeTroGen), Hospital Universitário Maria Aparecida Pedrossian (HUMAP), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil.
| | - Andreia Conceição Milan Brochado Antoniolli
- Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica (CeTroGen), Hospital Universitário Maria Aparecida Pedrossian (HUMAP), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil; Programa de Pós-graduação em Saúde e Desenvolvimento na Região Centro-Oeste, Faculdade de Medicina Dr. Hélio Mandetta (FAMED), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil.
| | - Andréa Luiza Cunha-Laura
- Programa de Mestrado em Farmácia, Faculdade de Ciências Farmacêuticas, Alimentos e Nutrição (FACFAN), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil.
| | - Rodrigo Juliano Oliveira
- Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica (CeTroGen), Hospital Universitário Maria Aparecida Pedrossian (HUMAP), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil; Programa de Mestrado em Farmácia, Faculdade de Ciências Farmacêuticas, Alimentos e Nutrição (FACFAN), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil; Programa de Pós-graduação em Saúde e Desenvolvimento na Região Centro-Oeste, Faculdade de Medicina Dr. Hélio Mandetta (FAMED), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil; Programa de Pós-graduação em Genética e Biologia Molecular, Centro de Ciências Biológicas (CCB), Universidade Estadual de Londrina (UEL), Londrina, Paraná, Brazil.
| |
Collapse
|
5
|
Vani JM, Monreal MTFD, Auharek SA, Cunha-Laura AL, de Arruda EJ, Lima AR, da Silva CM, Antoniolli-Silva ACMB, de Lima DP, Beatriz A, Oliveira RJ. The mixture of cashew nut shell liquid and castor oil results in an efficient larvicide against Aedes aegypti that does not alter embryo-fetal development, reproductive performance or DNA integrity. PLoS One 2018; 13:e0193509. [PMID: 29554095 PMCID: PMC5858748 DOI: 10.1371/journal.pone.0193509] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2017] [Accepted: 02/13/2018] [Indexed: 11/18/2022] Open
Abstract
Dengue fever, chikungunya fever and Zika virus are epidemics in Brazil that are transmitted by mosquitoes, such as Aedes aegypti or Aedes albopictus. The liquid from shells of cashew nuts is attractive for its important biological and therapeutic activities, which include toxicity to mosquitoes of the genus Aedes. The present study evaluated the effects of a mixture of surfactants from natural cashew nutshell liquid and castor oil (named TaLCC-20) on the mortality of larvae and on the reproductive performance, embryonic and fetal development and genetic stability of Swiss mice. A total of 400 Ae. aegypti larvae (third larval stage) were treated with TaLCC-20 concentrations of 0.05 mg/L, 0.5 mg/L, or 5 mg/L (ppm). Twenty pregnant female mice were also orally administered TaLCC-20 at doses of 5 mg/kg and 50 mg/kg body weight (b.w.), and 10 animals were given only drinking water at 0.1 mL/10 g b.w. (orally). The results of a larvicide test demonstrated that 5 mg/mL TaLCC-20 killed 100% of larvae within three hours, which is comparable to the gold standard indicated by the Ministry of Health. Overall, these results show that TaLCC-20 is an efficient larvicide that does not induce genetic damage. In addition, changes in reproductive performance and embryo-fetal development appear positive, and the formulation is cost effective. Therefore, TaLCC-20 is an important product in the exploration of natural larvicides and can assist in fighting mosquitos as vectors for dengue fever, chikungunya fever and Zika virus, which are emerging/re-emerging and require proper management to ensure minimal harm to the human population. Therefore, TaLCC-20 can be considered a key alternative to commercial products, which are effective yet toxigenic.
Collapse
Affiliation(s)
- Juliana Miron Vani
- Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica—CeTroGen, Hospital Universitário Maria Aparecida Pedrossian–HUMAP, Universidade Federal de Mato Grosso do Sul—UFMS, Campo Grande, MS, Brasil
- Programa de Mestrado em Farmácia, Faculdade de Ciências Farmacêuticas Alimentos e Nutrição—FACFAN, Universidade Federal de Mato Grosso do Sul–UFMS, Campo Grande, MS, Brasil
- Programa de Pós-graduação em Saúde e Desenvolvimento na Região Centro-Oeste, Faculdade de Medicina “Dr. Hélio Mandetta”–FAMED, Universidade Federal de Mato Grosso do Sul–UFMS, Campo Grande, MS, Brasil
| | - Maria Tereza Ferreira Duenhas Monreal
- Programa de Mestrado em Farmácia, Faculdade de Ciências Farmacêuticas Alimentos e Nutrição—FACFAN, Universidade Federal de Mato Grosso do Sul–UFMS, Campo Grande, MS, Brasil
| | - Sarah Alves Auharek
- Faculdade de Medicina do Mucuri, Universidade Federal dos Vales do Jequitinhonha e do Mucuri–UFVJM, Teófilo Otoni, MG, Brasil
| | - Andréa Luiza Cunha-Laura
- Programa de Mestrado em Farmácia, Faculdade de Ciências Farmacêuticas Alimentos e Nutrição—FACFAN, Universidade Federal de Mato Grosso do Sul–UFMS, Campo Grande, MS, Brasil
| | - Eduardo José de Arruda
- Faculdade de Ciências Exatas e Tecnologia–FACET, Universidade Federal da Grande Dourados–UFGD, Dourados, MS, Brasil
| | - Alessandra Ramos Lima
- Faculdade de Ciências Exatas e Tecnologia–FACET, Universidade Federal da Grande Dourados–UFGD, Dourados, MS, Brasil
| | - Cicera Maria da Silva
- Faculdade de Ciências Exatas e Tecnologia–FACET, Universidade Federal da Grande Dourados–UFGD, Dourados, MS, Brasil
| | - Andréia Conceição Milan Brochado Antoniolli-Silva
- Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica—CeTroGen, Hospital Universitário Maria Aparecida Pedrossian–HUMAP, Universidade Federal de Mato Grosso do Sul—UFMS, Campo Grande, MS, Brasil
- Programa de Pós-graduação em Saúde e Desenvolvimento na Região Centro-Oeste, Faculdade de Medicina “Dr. Hélio Mandetta”–FAMED, Universidade Federal de Mato Grosso do Sul–UFMS, Campo Grande, MS, Brasil
| | - Dênis Pires de Lima
- Programa de Mestrado em Farmácia, Faculdade de Ciências Farmacêuticas Alimentos e Nutrição—FACFAN, Universidade Federal de Mato Grosso do Sul–UFMS, Campo Grande, MS, Brasil
- Instituto de Química—INQUI, Universidade Federal de Mato Grosso do Sul–UFMS, Campo Grande, MS, Brasil
| | - Adilson Beatriz
- Programa de Mestrado em Farmácia, Faculdade de Ciências Farmacêuticas Alimentos e Nutrição—FACFAN, Universidade Federal de Mato Grosso do Sul–UFMS, Campo Grande, MS, Brasil
- Instituto de Química—INQUI, Universidade Federal de Mato Grosso do Sul–UFMS, Campo Grande, MS, Brasil
- * E-mail: (AB); (RJO)
| | - Rodrigo Juliano Oliveira
- Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica—CeTroGen, Hospital Universitário Maria Aparecida Pedrossian–HUMAP, Universidade Federal de Mato Grosso do Sul—UFMS, Campo Grande, MS, Brasil
- Programa de Mestrado em Farmácia, Faculdade de Ciências Farmacêuticas Alimentos e Nutrição—FACFAN, Universidade Federal de Mato Grosso do Sul–UFMS, Campo Grande, MS, Brasil
- Programa de Pós-graduação em Saúde e Desenvolvimento na Região Centro-Oeste, Faculdade de Medicina “Dr. Hélio Mandetta”–FAMED, Universidade Federal de Mato Grosso do Sul–UFMS, Campo Grande, MS, Brasil
- Programa de Pós-graduação em Genética e Biologia Molecular, Centro de Ciências Biológicas–CCB, Universidade Estadual de Londrina, Londrina, PR, Brasil
- * E-mail: (AB); (RJO)
| |
Collapse
|
6
|
Schneider BUC, Meza A, Beatriz A, Pesarini JR, Carvalho PCD, Mauro MDO, Karaziack CB, Cunha-Laura AL, Monreal ACD, Matuo R, Lima DPD, Oliveira RJ. Cardanol: toxicogenetic assessment and its effects when combined with cyclophosphamide. Genet Mol Biol 2016; 39:279-89. [PMID: 27303909 PMCID: PMC4910563 DOI: 10.1590/1678-4685-gmb-2015-0170] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2015] [Accepted: 12/20/2015] [Indexed: 01/17/2023] Open
Abstract
Cardanol is an effective antioxidant and is a compound with antimutagenic and
antitumoral activity. Here, we evaluated the genotoxic and mutagenic potential of
saturated side chain cardanol and its effects in combination with cyclophosphamide in
preventing DNA damage, apoptosis, and immunomodulation. Swiss mice were treated with
cardanol (2.5, 5 and 10 mg/kg) alone or in combination with cyclophosphamide (100
mg/kg). The results showed that cardanol is an effective chemopreventive compound,
with damage reduction percentages that ranged from 18.9 to 31.76% in the comet assay
and from 45 to 97% in the micronucleus assay. Moreover, cardanol has the ability to
reduce the frequency of apoptosis induced by cyclophosphamide. The compound did not
show immunomodulatory activity. A final interpretation of the data showed that,
despite its chemoprotective capacity, cardanol has a tendency to induce DNA damage.
Hence, caution is needed if this compound is used as a chemopreventive agent. Also,
this compound is likely not suitable as an adjuvant in chemotherapy treatments that
use cyclophosphamide.
Collapse
Affiliation(s)
- Beatriz Ursinos Catelan Schneider
- Programa de Pós-Graduação em Saúde e Desenvolvimento na Região Centro-Oeste, Faculdade de Medicina "Dr. Hélio Mandetta", Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil.,Centro de Estudos em Células-Tronco, Terapia Celular e Genética Toxicológica, Hospital Universitário "Maria Aparecida Pedrossian", Empresa Brasileira de Serviços Hospitalares, Campo Grande, MS, Brazil
| | - Alisson Meza
- Programa de Pós-Graduação em Química, Instituto de Química, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil
| | - Adilson Beatriz
- Programa de Pós-Graduação em Química, Instituto de Química, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil.,Programa de Mestrado em Farmácia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil
| | - João Renato Pesarini
- Programa de Pós-Graduação em Saúde e Desenvolvimento na Região Centro-Oeste, Faculdade de Medicina "Dr. Hélio Mandetta", Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil.,Centro de Estudos em Células-Tronco, Terapia Celular e Genética Toxicológica, Hospital Universitário "Maria Aparecida Pedrossian", Empresa Brasileira de Serviços Hospitalares, Campo Grande, MS, Brazil
| | - Pamela Castilho de Carvalho
- Programa de Pós-Graduação em Saúde e Desenvolvimento na Região Centro-Oeste, Faculdade de Medicina "Dr. Hélio Mandetta", Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil.,Centro de Estudos em Células-Tronco, Terapia Celular e Genética Toxicológica, Hospital Universitário "Maria Aparecida Pedrossian", Empresa Brasileira de Serviços Hospitalares, Campo Grande, MS, Brazil
| | - Mariana de Oliveira Mauro
- Programa de Doutorado em Biotecnologia e Biodiversidade - Rede Pró Centro-Oeste, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil
| | - Caroline Bilhar Karaziack
- Programa de Pós-Graduação em Química, Instituto de Química, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil
| | - Andréa Luiza Cunha-Laura
- Programa de Mestrado em Farmácia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil
| | - Antônio Carlos Duenhas Monreal
- Programa de Mestrado em Farmácia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil
| | - Renata Matuo
- Centro de Estudos em Células-Tronco, Terapia Celular e Genética Toxicológica, Hospital Universitário "Maria Aparecida Pedrossian", Empresa Brasileira de Serviços Hospitalares, Campo Grande, MS, Brazil.,Programa de Mestrado em Farmácia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil
| | - Dênis Pires de Lima
- Programa de Pós-Graduação em Química, Instituto de Química, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil
| | - Rodrigo Juliano Oliveira
- Programa de Pós-Graduação em Saúde e Desenvolvimento na Região Centro-Oeste, Faculdade de Medicina "Dr. Hélio Mandetta", Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil.,Centro de Estudos em Células-Tronco, Terapia Celular e Genética Toxicológica, Hospital Universitário "Maria Aparecida Pedrossian", Empresa Brasileira de Serviços Hospitalares, Campo Grande, MS, Brazil.,Programa de Mestrado em Farmácia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil
| |
Collapse
|
7
|
Martello MD, David N, Matuo R, Carvalho PC, Navarro SD, Monreal ACD, Cunha-Laura AL, Cardoso CAL, Kassuya CAL, Oliveira RJ. Campomanesia adamantium extract induces DNA damage, apoptosis, and affects cyclophosphamide metabolism. Genet Mol Res 2016; 15:gmr7678. [PMID: 27173259 DOI: 10.4238/gmr.15027678] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Campomanesia adamantium (Cambess.) O. Berg. is originally from Brazil. Its leaves and fruits have medicinal properties such as anti-inflammatory, antidiarrheal and antiseptic properties. However, the mutagenic potential of this species has been reported in few studies. This study describes the mutagenic/antimutagenic, splenic phagocytic, and apoptotic activities of C. adamantium hydroethanolic extract with or without cyclophosphamide in Swiss mice. The animals orally received the hydroethanolic extract at doses of 30, 100, or 300 mg/kg with or without 100 mg/kg cyclophosphamide. Mutagenesis was evaluated by performing the micronucleus assay after treatment for 24, 48, and 72 h, while splenic phagocytic and apoptotic effects were investigated after 72 h. Short-term exposure of 30 and 100 mg/kg extract induced mild clastogenic/aneugenic effects and increased splenic phagocytosis and apoptosis in the liver, spleen, and kidneys. When the extract was administered in combination with cyclophosphamide, micronucleus frequency and apoptosis reduced. Extract components might affect cyclophosphamide metabolism, which possibly leads to increased clearance of this chemotherapeutic agent. C. adamantium showed mutagenic activity and it may decrease the effectiveness of drugs with metabolic pathways similar to those associated with cyclophosphamide. Thus, caution should be exercised while consuming these extracts, especially when received in combination with other drugs.
Collapse
Affiliation(s)
- M D Martello
- Centro de Células Tronco, Terapia Celular e Genética Toxicológica, Hospital Universitário "Maria Aparecida Pedrossian", EBSERH, Campo Grande, MS, Brasil.,Programa de Mestrado em Farmácia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brasil
| | - N David
- Centro de Células Tronco, Terapia Celular e Genética Toxicológica, Hospital Universitário "Maria Aparecida Pedrossian", EBSERH, Campo Grande, MS, Brasil.,Programa de Mestrado em Farmácia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brasil
| | - R Matuo
- Programa de Mestrado em Farmácia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brasil
| | - P C Carvalho
- Centro de Células Tronco, Terapia Celular e Genética Toxicológica, Hospital Universitário "Maria Aparecida Pedrossian", EBSERH, Campo Grande, MS, Brasil.,Programa de Pós-Graduação em Saúde e Desenvolvimento da Região Centro-Oeste, Faculdade de Medicina Dr. Hélio Mandetta, Campo Grande, MS, Brasil
| | - S D Navarro
- Programa de Pós-Graduação em Biotecnologia e Biodiversidade, Rede Pró-Centro-Oeste, Instituto de Química
| | - A C D Monreal
- Programa de Mestrado em Farmácia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brasil
| | - A L Cunha-Laura
- Programa de Mestrado em Farmácia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brasil
| | - C A L Cardoso
- Curso de Graduação em Química, Universidade Estadual de Mato Grosso do Sul, Dourados, MS, Brasil
| | - C A L Kassuya
- Curso de Ciências da Saúde, Universidade Federal da Grande Dourados, Dourados, MS, Brasil
| | - R J Oliveira
- Centro de Células Tronco, Terapia Celular e Genética Toxicológica, Hospital Universitário "Maria Aparecida Pedrossian", EBSERH, Campo Grande, MS, Brasil.,Programa de Mestrado em Farmácia, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brasil.,Programa de Pós-Graduação em Saúde e Desenvolvimento da Região Centro-Oeste, Faculdade de Medicina Dr. Hélio Mandetta, Campo Grande, MS, Brasil
| |
Collapse
|
8
|
Carvalho PC, Santos EA, Schneider BUC, Matuo R, Pesarini JR, Cunha-Laura AL, Monreal ACD, Lima DP, Antoniolli ACMB, Oliveira RJ. Diaryl sulfide analogs of combretastatin A-4: Toxicogenetic, immunomodulatory and apoptotic evaluations and prospects for use as a new chemotherapeutic drug. Environ Toxicol Pharmacol 2015; 40:715-721. [PMID: 26410090 DOI: 10.1016/j.etap.2015.08.028] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/18/2015] [Revised: 08/23/2015] [Accepted: 08/30/2015] [Indexed: 06/05/2023]
Abstract
Combretastatin A-4 exhibits efficient anti-cancer potential in human tumors, including multidrug-resistant tumors. We evaluated the mutagenic, apoptotic and immunomodulatory potential of two diaryl sulfide analogs of combretastatin A-4, 1,2,3-trimethoxy-5-([4-methoxy-3-nitrophenyl]thio)benzene (analog 1) and 1,2,3-trimethoxy-5-([3-amino-4-methoxyphenyl]thio)benzene (analog 2), as well as their association with the anti-tumor agent cyclophosphamide, in Swiss mice. Such evaluation was achieved using the comet assay, peripheral blood micronucleus test, splenic phagocytosis assay, and apoptosis assay. Both analogs were found to be genotoxic, mutagenic and to induce apoptosis. They also increased splenic phagocytosis, although this increase was more pronounced for analog 2. When combined with cyclophosphamide, analog 1 enhanced the mutagenic and apoptotic effects of this anti-tumor agent. In contrast, analog 2 did not enhance the effects of cyclophosphamide and prevented apoptosis at lower doses. These data suggest that analog 1 could be an adjuvant chemotherapeutic agent and possibly improve the anti-neoplastic effect of cyclophosphamide. Additionally, this compound could be a candidate chemotherapeutic agent and/or an adjuvant for use in combined anti-cancer therapy.
Collapse
Affiliation(s)
- Pamela Castilho Carvalho
- Center for Stem Cells, Cell Therapy and Genetic Toxicology Studies (Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen), Maria Aparecida Pedrossian University Hospital (Hospital Universitário Maria Aparecida Pedrossian), EBSERH (Empresa Brasileira de Serviços Hospitalares), Campo Grande, Mato Grosso do Sul, Brazil; Graduate Program in Health and Development in the Midwestern Region, Medical School (Faculdade Medicina - FAMED), UFMS, Campo Grande, Mato Grosso do Sul, Brazil
| | - Edson Anjos Santos
- Biochemistry Laboratory, Center for Biological and Health Sciences, Federal University of Mato Grosso do Sul (Universidade Federal do Mato Grosso do Sul - UFMS), Campo Grande, Mato Grosso do Sul, Brazil
| | - Beatriz Ursinos Catelán Schneider
- Center for Stem Cells, Cell Therapy and Genetic Toxicology Studies (Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen), Maria Aparecida Pedrossian University Hospital (Hospital Universitário Maria Aparecida Pedrossian), EBSERH (Empresa Brasileira de Serviços Hospitalares), Campo Grande, Mato Grosso do Sul, Brazil; Graduate Program in Health and Development in the Midwestern Region, Medical School (Faculdade Medicina - FAMED), UFMS, Campo Grande, Mato Grosso do Sul, Brazil
| | - Renata Matuo
- Center for Stem Cells, Cell Therapy and Genetic Toxicology Studies (Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen), Maria Aparecida Pedrossian University Hospital (Hospital Universitário Maria Aparecida Pedrossian), EBSERH (Empresa Brasileira de Serviços Hospitalares), Campo Grande, Mato Grosso do Sul, Brazil; Master's Program in Pharmacy, Center for Biological and Health Sciences (Centro de Ciências Biológicas e da Saúde - CCBS), UFMS, Campo Grande, Mato Grosso do Sul, Brazil
| | - João Renato Pesarini
- Center for Stem Cells, Cell Therapy and Genetic Toxicology Studies (Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen), Maria Aparecida Pedrossian University Hospital (Hospital Universitário Maria Aparecida Pedrossian), EBSERH (Empresa Brasileira de Serviços Hospitalares), Campo Grande, Mato Grosso do Sul, Brazil; Graduate Program in Health and Development in the Midwestern Region, Medical School (Faculdade Medicina - FAMED), UFMS, Campo Grande, Mato Grosso do Sul, Brazil
| | - Andréa Luiza Cunha-Laura
- Master's Program in Pharmacy, Center for Biological and Health Sciences (Centro de Ciências Biológicas e da Saúde - CCBS), UFMS, Campo Grande, Mato Grosso do Sul, Brazil
| | - Antônio Carlos Duenhas Monreal
- Master's Program in Pharmacy, Center for Biological and Health Sciences (Centro de Ciências Biológicas e da Saúde - CCBS), UFMS, Campo Grande, Mato Grosso do Sul, Brazil
| | - Dênis Pires Lima
- Graduate Program in Chemistry, Institute of Chemistry (Instituto de Química - IQ), UFMS, Campo Grande, Mato Grosso do Sul, Brazil
| | - Andréia Conceição Milan Brochado Antoniolli
- Center for Stem Cells, Cell Therapy and Genetic Toxicology Studies (Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen), Maria Aparecida Pedrossian University Hospital (Hospital Universitário Maria Aparecida Pedrossian), EBSERH (Empresa Brasileira de Serviços Hospitalares), Campo Grande, Mato Grosso do Sul, Brazil; Graduate Program in Health and Development in the Midwestern Region, Medical School (Faculdade Medicina - FAMED), UFMS, Campo Grande, Mato Grosso do Sul, Brazil
| | - Rodrigo Juliano Oliveira
- Center for Stem Cells, Cell Therapy and Genetic Toxicology Studies (Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen), Maria Aparecida Pedrossian University Hospital (Hospital Universitário Maria Aparecida Pedrossian), EBSERH (Empresa Brasileira de Serviços Hospitalares), Campo Grande, Mato Grosso do Sul, Brazil; Graduate Program in Health and Development in the Midwestern Region, Medical School (Faculdade Medicina - FAMED), UFMS, Campo Grande, Mato Grosso do Sul, Brazil; Master's Program in Pharmacy, Center for Biological and Health Sciences (Centro de Ciências Biológicas e da Saúde - CCBS), UFMS, Campo Grande, Mato Grosso do Sul, Brazil.
| |
Collapse
|
9
|
Oliveira RJ, Navarro SD, de Lima DP, Meza A, Pesarini JR, da Silva Gomes R, Karaziack CB, de Oliveira Mauro M, Cunha-Laura AL, Monreal ACD, Romão W, Júnior VL, Beatriz A. A novel cytosporone 3-Heptyl-4,6-dihydroxy-3H-isobenzofuran-1-one: synthesis; toxicological, apoptotic and immunomodulatory properties; and potentiation of mutagenic damage. BMC Cancer 2015; 15:561. [PMID: 26228542 PMCID: PMC4520062 DOI: 10.1186/s12885-015-1532-2] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2014] [Accepted: 07/02/2015] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND A large number of studies are attempting to identify alternative products from natural sources or synthesized compounds that effectively interact with cancer cells without causing adverse effects on healthy cells. Resorcinolic lipids are a class of bioactive compounds that possess anticancer activity and are able to interact with the lipid bilayer. Therefore, the objective of this study was to synthesize a novel resorcinolic lipid and test its biological proprieties. METHODS We aimed to synthesize a novel resorcinolic lipid belonging to the class of cytosporones, AMS049 (3-Heptyl-4,6-dihydroxy-3H-isobenzofuran-1-one) and to evaluate the toxicity of two concentrations of this lipid (7.5 and 10 mg/kg) by determining its genotoxic, mutagenic, immunomodulatory, and apoptotic effects, as well as any biochemical and histopathological alterations in mice treated with cyclophosphamide. The results were analyzed by ANOVA followed by the Tukey test A . level of significance of p < 0.05 was adopted. RESULTS The new cytosporone AMS049 was synthesized in only three steps and in satisfactory yields. The results indicate that the compound is neither genotoxic nor mutagenic and does not alter biochemical parameters. The histological alterations observed in the liver and kidneys did not compromise the function of these organs. Histology of the spleen suggested immunomodulation, although no changes were observed in splenic phagocytosis or differential blood cell count. The results also show that AMS049 potentiates the mutagenic effect of the chemotherapy drug cyclophosphamide and that the combination induces apoptosis. CONCLUSION These facts indicate a potential therapeutic application of this novel cytosporone as an important chemotherapeutic adjuvant.
Collapse
Affiliation(s)
- Rodrigo Juliano Oliveira
- Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen, Hospital Universitário "Maria Aparecida Pedrossian" - HUMAP, Empresa Brasileira de Serviços Hospitalares - EBSERH, Campo Grande, MS, Brazil. .,Programa de Mestrado em Farmácia, Centro de Ciências Biológicas e da Saúde - CCBS, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil. .,Programa de Pós-graduação em Saúde e Desenvolvimento na Região Centro-Oeste, Faculdade de Medicina "Dr. Hélio Mandetta" - FAMED, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil.
| | - Stephanie Dynczuki Navarro
- Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen, Hospital Universitário "Maria Aparecida Pedrossian" - HUMAP, Empresa Brasileira de Serviços Hospitalares - EBSERH, Campo Grande, MS, Brazil. .,Programa de Mestrado em Farmácia, Centro de Ciências Biológicas e da Saúde - CCBS, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil.
| | - Dênis Pires de Lima
- Programa de Mestrado em Farmácia, Centro de Ciências Biológicas e da Saúde - CCBS, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil. .,Programa de Pós-graduação em Química, Instituto de Química, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil.
| | - Alisson Meza
- Programa de Pós-graduação em Química, Instituto de Química, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil.
| | - João Renato Pesarini
- Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen, Hospital Universitário "Maria Aparecida Pedrossian" - HUMAP, Empresa Brasileira de Serviços Hospitalares - EBSERH, Campo Grande, MS, Brazil. .,Programa de Pós-graduação em Saúde e Desenvolvimento na Região Centro-Oeste, Faculdade de Medicina "Dr. Hélio Mandetta" - FAMED, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil.
| | - Roberto da Silva Gomes
- Programa de Pós-graduação em Química, Instituto de Química, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil. .,Faculdade de Ciências Exatas e Tecnologia - FACET, Universidade Federal da Grande Dourados - UFGD, Dourados, MS, Brazil.
| | - Caroline Bilhar Karaziack
- Programa de Pós-graduação em Química, Instituto de Química, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil.
| | - Mariana de Oliveira Mauro
- Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica - CeTroGen, Hospital Universitário "Maria Aparecida Pedrossian" - HUMAP, Empresa Brasileira de Serviços Hospitalares - EBSERH, Campo Grande, MS, Brazil. .,Programa de Doutorado em Biotecnologia e Biodiversidade - Rede Pró Centro-Oeste, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil.
| | - Andréa Luiza Cunha-Laura
- Centro de Ciências Biológicas e da Saúde - CCBS, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil.
| | - Antônio Carlos Duenhas Monreal
- Centro de Ciências Biológicas e da Saúde - CCBS, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil.
| | - Wanderson Romão
- Departamento de Química, Universidade Federal do Espírito Santo - UFES, Vitória, ES, Brazil.
| | - Valdemar Lacerda Júnior
- Departamento de Química, Universidade Federal do Espírito Santo - UFES, Vitória, ES, Brazil.
| | - Adilson Beatriz
- Programa de Mestrado em Farmácia, Centro de Ciências Biológicas e da Saúde - CCBS, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil. .,Programa de Pós-graduação em Química, Instituto de Química, Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, MS, Brazil.
| |
Collapse
|
10
|
Rocha RS, Kassuya CAL, Formagio ASN, Mauro MDO, Andrade-Silva M, Monreal ACD, Cunha-Laura AL, Vieira MDC, Oliveira RJ. Analysis of the anti-inflammatory and chemopreventive potential and description of the antimutagenic mode of action of the Annona crassiflora methanolic extract. Pharm Biol 2015; 54:35-47. [PMID: 25885939 DOI: 10.3109/13880209.2015.1014567] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
CONTEXT Annona crassiflora Mart. (Annonaceae) is a medicinal plant that is widely used in folk medicine, which leads to its investigation as a potential source of new pharmacological principles. OBJECTIVE This study describes the anti-inflammatory, antiallodynic, and antimutagenic/chemopreventive activities of the leaves A. crassiflora methanolic extract. Its antimutagenic mode of action was analyzed in a plant or animal experimental model. MATERIALS AND METHODS Total flavonoids were quantified by spectrophotometry at 415 nm and its composition was analyzed by (1)H NMR spectra. Animals received orally, 30, 100, and 300 mg/kg of extract in both tests, carrageenan-induced paw edema and myeloperoxidase activity. Animals were treated with 100 and 300 mg/kg, in all the analyzed tests, pleural cell migration and protein exudation, carrageenan-induced cell migration into the pouch, induction of joint inflammation and carrageenan-induced allodynia response in the mouse paw. To evaluate the antimutagenic/chemopreventive activity through the Allium cepa test, we used 5, 10, and 15 mg/L of extract, and for the micronucleus test in the peripheral blood, we used the dose of 15 mg/kg. RESULTS The fractionation of the ethyl acetate (EA) fraction, resulting from the partition of the methanol extract of the A. crassiflora, afforded through chromatographic methods resulted in the isolation of kaempferol 3-O-β-glucoside and kaempferol 3-O-β-diglucoside. Oral treatment with 100 and 300 mg/kg of extract significantly inhibited the carrageenan-induced edema formation, with inhibitions of 53 ± 7% and 47 ± 10%; in MPO activity, the observed inhibitions were 60 ± 7% for 100 mg/kg treatment and 63 ± 7% for 300 mg/kg. The ACME reduced significantly the total leukocytes (an inhibition of 78 ± 9% with 100 mg/kg and 90 ± 7% with 300 mg/kg) and protein levels (approximately 100% inhibition with both doses) in the pleurisy model. In carrageenan-induced leukocyte migration into the pouch, the extract inhibited leukocyte migration only when administered 300 mg/kg per dose (the reduction was 43 ± 5%). Pretreatment with extract failed to reduce the zymosan-induced edema formation and did not inhibit the carrageenan-induced mechanical allodynia. Damage reduction in Allium cepa tested with different concentrations (5, 10, and 15 mg/L) was 66.17, 75.75, and 69.19% for the pre-treatment; 72.72, 33.33, and 22.22% for the simple simultaneous treatment; 100.50, 93.93, and 102.52% for the simultaneous treatment with pre-incubation; 89.39, 79.79, and 84.34%; for the post-treatment, and 86.36, 81.31, and 93.43% for the continuous treatment. The antimutagenic evaluation in the micronucleous test showed a damage reduction of 75.00 and 64.58% for the pre-treatment and simultaneous protocols, respectively. The post-treatment protocol increased the cyclophosphamide effects in 45.83%. CONCLUSION These results suggest that this medicinal plant has chemopreventive and anti-inflammatory therapeutic potential.
Collapse
Affiliation(s)
- Roberta Schroder Rocha
- a Center of Studies in Stem Cells, Cell Therapy and Genetic Toxicology (CeTroGen), University Hospital (NHU), Federal University of Mato Grosso do Sul (UFMS) , Campo Grande , MS , Brazil
- b Center of Biological and Health Sciences (CCBS), Federal University of Mato Grosso do Sul (UFMS) , Campo Grande , MS , Brazil
| | | | | | - Mariana de Oliveira Mauro
- a Center of Studies in Stem Cells, Cell Therapy and Genetic Toxicology (CeTroGen), University Hospital (NHU), Federal University of Mato Grosso do Sul (UFMS) , Campo Grande , MS , Brazil
- e Midwest Pro Network - Graduate Program in Biotechnology and Biodiversity, Federal University of Mato Grosso do Sul (UFMS) , Campo Grande , MS , Brazil
| | - Magaiver Andrade-Silva
- c Faculty of Health Sciences (FCS), Federal University of Grande Dourados (UFGD) , Dourados , MS , Brazil
| | - Antonio Carlos Duenhas Monreal
- b Center of Biological and Health Sciences (CCBS), Federal University of Mato Grosso do Sul (UFMS) , Campo Grande , MS , Brazil
| | - Andréa Luiza Cunha-Laura
- b Center of Biological and Health Sciences (CCBS), Federal University of Mato Grosso do Sul (UFMS) , Campo Grande , MS , Brazil
- f Master's Programme in Pharmacy, Center of Biological and Health Sciences (CCBS), Federal University of Mato Grosso do Sul (UFMS) , Campo Grande , MS , Brazil , and
| | - Maria do Carmo Vieira
- d Faculty of Agricultural Sciences (FCA), Federal University of Grande Dourados (UFGD) , Dourados , MS , Brazil
| | - Rodrigo Juliano Oliveira
- a Center of Studies in Stem Cells, Cell Therapy and Genetic Toxicology (CeTroGen), University Hospital (NHU), Federal University of Mato Grosso do Sul (UFMS) , Campo Grande , MS , Brazil
- f Master's Programme in Pharmacy, Center of Biological and Health Sciences (CCBS), Federal University of Mato Grosso do Sul (UFMS) , Campo Grande , MS , Brazil , and
- g Graduate Program in Health and Development in the Midwest Region, School of Medicine "Dr. Hélio Mandetta" (FAMED), Federal University of Mato Grosso do Sul (UFMS) , Campo Grande , MS , Brazil
| |
Collapse
|
11
|
David ND, Mauro MDO, Gonçalves CA, Pesarini JR, Strapasson RLB, Kassuya CAL, Stefanello MÉA, Cunha-Laura AL, Monreal ACD, Oliveira RJ. Gochnatia polymorpha ssp. floccosa: bioprospecting of an anti-inflammatory phytotherapy for use during pregnancy. J Ethnopharmacol 2014; 154:370-9. [PMID: 24727192 DOI: 10.1016/j.jep.2014.04.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/03/2014] [Revised: 03/19/2014] [Accepted: 04/03/2014] [Indexed: 05/22/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Gochnatia polymorpha ssp. floccosa is used in folk medicine to treat inflammation and infections. Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly consumed medications during pregnancy in women with inflammatory diseases. However, the relationship between the use of NSAIDs and the risk of miscarriage and birth defects and/or benefits is not fully understood. Thus, an investigation regarding the use of Gochnatia polymorpha during gestation is of relevance for developing safe anti-inflammatory drugs for use during pregnancy. MATERIALS AND METHODS The pregnant females were randomly divided into 5 groups. Control group received a hydroalcoholic solution (1.2%), via gavage, for at least 15 days prior to mating and throughout the gestational period. The pre-treatment group received Gochnatia polymorpha ethanol extract (GPEE), via gavage, at a dose of 100mg/kg body weight (b.w.) for at least 15 days prior to mating and up to the appearance of the vaginal plug. The organogenesis group received GPEE at a dose of 100mg/kg (b.w.), via gavage, on the 5-15th gestacional day. The pregnancy group received GPEE at a dose of 100mg/kg (b.w.), via gavage, throughout the gestational period (from the 1st to the 18th day of pregnancy). The pre+pregnancy group received GPEE at a dose of 100mg/kg (b.w.), via gavage, for at least 15 days prior to mating and throughout the entire gestational period. The clinical signals of maternal toxicity and teratogenesis were evaluated. Additional assays to evaluate chronic inflammation, antigenotoxicity and immunomodolatory activity were performed. RESULTS AND CONCLUSIONS The results indicated that GPEE does not interfere with reproductive performance or embryo-fetal development but does correlate with reduced weight and fetal length. The extract was not teratogenic or mutagenic or an immunomodulator. However, GPEE did exhibit effective anti-inflammatory activity. Based on this study, it can be inferred that GPEE is an important, safe anti-inflammatory agent for use during pregnancy according to the experimental design we utilized, which opens up possibilities for the bioprospecting of a new anti-inflammatory phytotherapy for use during pregnancy.
Collapse
Affiliation(s)
- Natan de David
- Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica (CeTroGen), Núcleo de Hospital Universitário (NHU), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil; Programa de Mestrado em Farmácia, Centro de Ciências Biológicas e da Saúde (CCBS), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil
| | - Mariana de Oliveira Mauro
- Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica (CeTroGen), Núcleo de Hospital Universitário (NHU), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil; Programa de Pós-graduação em Biotecnologia e Biodiversidade - Rede Pró Centro-Oeste, Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil
| | - Caroline Amélia Gonçalves
- Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica (CeTroGen), Núcleo de Hospital Universitário (NHU), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil
| | - João Renato Pesarini
- Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica (CeTroGen), Núcleo de Hospital Universitário (NHU), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil; Programa de Pós-graduação em Saúde e Desenvolvimento na Região Centro-Oeste, Faculdade de Medicina "Dr. Hélio Mandetta" (FAMED), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil
| | | | | | | | - Andréa Luiza Cunha-Laura
- Programa de Mestrado em Farmácia, Centro de Ciências Biológicas e da Saúde (CCBS), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil
| | - Antônio Carlos Duenhas Monreal
- Centro de Ciências Biológicas e da Saúde (CCBS), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil
| | - Rodrigo Juliano Oliveira
- Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica (CeTroGen), Núcleo de Hospital Universitário (NHU), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil; Programa de Mestrado em Farmácia, Centro de Ciências Biológicas e da Saúde (CCBS), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil; Programa de Pós-graduação em Saúde e Desenvolvimento na Região Centro-Oeste, Faculdade de Medicina "Dr. Hélio Mandetta" (FAMED), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil.
| |
Collapse
|
12
|
Navarro SD, Beatriz A, Meza A, Pesarini JR, Gomes RDS, Karaziack CB, Cunha-Laura AL, Monreal ACD, Romão W, Lacerda Júnior V, Mauro MDO, Oliveira RJ. A new synthetic resorcinolic lipid 3-Heptyl-3,4,6-trimethoxy-3H-isobenzofuran-1-one: Evaluation of toxicology and ability to potentiate the mutagenic and apoptotic effects of cyclophosphamide. Eur J Med Chem 2014; 75:132-42. [DOI: 10.1016/j.ejmech.2014.01.057] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2013] [Revised: 01/27/2014] [Accepted: 01/29/2014] [Indexed: 01/21/2023]
|
13
|
Gonçalves CA, Siqueira JM, Carollo CA, Mauro MDO, de Davi N, Cunha-Laura AL, Monreal ACD, Castro AH, Fernandes L, Chagas RR, Auharek SA, Oliveira RJ. Gestational exposure to Byrsonima verbascifolia: teratogenicity, mutagenicity and immunomodulation evaluation in female Swiss mice. J Ethnopharmacol 2013; 150:843-50. [PMID: 24140582 DOI: 10.1016/j.jep.2013.09.012] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/12/2013] [Revised: 09/01/2013] [Accepted: 09/06/2013] [Indexed: 05/22/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Byrsonima verbascifolia is used in folk medicine to treat diarrhea, intestinal infections, chronic wounds, Chagas disease, inflammation and as a diuretic. However there is no investigation regarding the Byrsonima verbascifolia hydrometanolic extract (BVHME) used during gestation. MATERIALS AND METHODS The pregnant females were randomly divided into 5 groups. Control group received saline plus DMSO (1%) in a volume of 0.1 mL/10 g (b.w.), via gavage, for at least 15 days prior to mating and throughout the gestational period. The Pre-treatment group received the BVHME, via gavage, at a dose of 50 mg/kg (b.w.) for at least 15 days prior to mating and up to the appearance of the vaginal plug. The Organogenesis group received the BVHME at a dose of 50 mg/kg (b.w.), via gavage, on the 5-15th gestational day. The Gestational group received the BVHME at a dose of 50 mg/kg (b.w.), via gavage, throughout the gestational period (from the 1st to the 18th day of pregnancy). The Pre+Gestational group received the BVHME at a dose of 50mg/kg (b.w.), via gavage, for at least 15 days prior to mating and up to throughout the gestational period. The clinical signals of maternal and fetuses toxicity were evaluated, as the mutagenicity and immunomodulation tests were performed. RESULTS AND CONCLUSIONS The present investigation shows, for the first time, that the use of Byrsonima verbascifolia extract in pregnant Swiss mice, did not alter the female reproductive function, mutagenicity or immunostimulation as well as not interfere with embryofetal development at least in our experimental conditions.
Collapse
Affiliation(s)
- Caroline Amélia Gonçalves
- Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica (CeTroGen), Núcleo de Hospital Universitário (NHU), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil; Programa de Pós-graduação em Farmácia, Centro de Ciências Biológicas e da Saúde (CCBS), Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Auharek SA, do Carmo Vieira M, Cardoso CAL, Oliveira RJ, Cunha-Laura AL. Reproductive toxicity of Campomanesia xanthocarpa (Berg.) in female Wistar rats. J Ethnopharmacol 2013; 148:341-343. [PMID: 23603192 DOI: 10.1016/j.jep.2013.04.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/07/2013] [Revised: 03/26/2013] [Accepted: 04/02/2013] [Indexed: 06/02/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE There is no evidence in the literature that substantiates the safety of Campomanesia xanthocarpa (Berg.) use during pregnancy. MATERIALS AND METHODS Thirty three female rats were randomly assigned to three groups. One group of animals received the Campomanesia xanthocarpa extract via gavage at a dose of 26.3mg/kg/day from 6 to 15 days of pregnancy (organogenic period, T1) and another group received the same extract throughout the gestational period (from the 1st to the 20th day of pregnancy, T2). Control groups received distilled water. Euthanasia was done on 20th day, when the liver, kidney, spleen ovaries, fetuses and their respective placentas were removed. Implantations, reabsorptions, live and dead fetuses were recorded. RESULTS AND CONCLUSIONS Campomanesia xanthocarpa, in these experimental conditions, did not disturb the reproductive function of female rats and did not interrupt the progress of the embryofetal development. Moreover, our results provide further evidence that the Campomanesia xanthocarpa treatment reduces reabsorption sites, increases placenta weight and the number of live fetuses and may therefore have therapeutic applications.
Collapse
Affiliation(s)
- Sarah Alves Auharek
- Centre of Biological Sciences and Health, Federal University of Mato Grosso do Sul, Campo Grande, MS, Brazil
| | | | | | | | | |
Collapse
|
15
|
Cunha-Laura AL, Juliano Oliveira R, de Barros ALC, de Siqueira JM, Carmo Vieira MD, Alves Auharek S. Maternal exposure to Cochlospermum regium: a toxicological evaluation. Revista Brasileira de Farmacognosia 2013. [DOI: 10.1590/s0102-695x2013005000005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|